ライフサイエンスコーパス: angiotensin-converting enzyme

1 up that includes the antihypertensive target angiotensin converting enzyme.

2 alpha2-macroglobulin, antithrombin III, and angiotensin-converting enzyme.

3 poglycorrhachia (11%, p = 0.25) and elevated angiotensin-converting enzyme (18%, p = 0.30) were exclu

4 Angiotensin converting enzyme 2 (ACE2) is a negative reg

5 on with enhanced BP, decreased expression of angiotensin converting enzyme 2, and increased expressio

6 protein with approximately 50% homology with angiotensin converting enzyme 2, but without a catalytic

7 Angiotensin-converting enzyme 2 (ACE2) and its product,

8 ent study showed that directed expression of angiotensin-converting enzyme 2 (ACE2) on cells previous

9 by adipocytes, can be catabolized by adipose angiotensin-converting enzyme 2 (ACE2) to form Ang(1-7).

10 With the discovery of the angiotensin-converting enzyme 2 (ACE2), a protective axi

11 mploy the same receptor for host cell entry, angiotensin-converting enzyme 2 (ACE2), but it is largel

12 interface between the RBD and its receptor, angiotensin-converting enzyme 2 (ACE2), to assess their

13 ive arm of the renin angiotensin system, the angiotensin-converting enzyme 2 (ACE2)/angiotensin-(1-7)

14 No changes in bronchoalveolar lavage fluid angiotensin-converting enzyme 2 activity were found.

15 The angiotensin-converting enzyme 2 and angiotensin-(1-7) (A

16 The conversion is catalyzed by angiotensin-converting enzyme 2 and other enzymes that s

17 was lower in fetal growth restriction in an angiotensin-converting enzyme 2 knockout mouse model cha

18 Since angiotensin-converting enzyme 2 metabolizes angiotensin

19 Recently, recombinant angiotensin-converting enzyme 2 was shown to protect mic

20 Unlike angiotensin-converting enzyme 2, collectrin lacks any ca

21 renin-angiotensin system and is a homolog of angiotensin-converting enzyme 2, sharing approximately 5

22 n system, angiotensin-converting enzyme, and angiotensin-converting enzyme 2.

23 ) exchanger 3, agonists of components of the angiotensin-converting enzyme 2/angiotensin(1-7)/Mas rec

24 In this paper, we report that angiotensin-converting enzyme-2 (ACE2) protected against

25 eptapeptide generated by catalytic action of angiotensin-converting enzyme-2 angiotensin A or directl

26 Angiotensin-converting-enzyme-2 (ACE2) has been describe

27 olase PP for 1h (STP-C1) had the most potent angiotensin converting enzyme (ACE) and dipeptidyl pepti

28 Adult mice were treated with an angiotensin converting enzyme (ACE) inhibitor, captopril

29 lure with reduced ejection fraction, such as angiotensin converting enzyme (ACE) inhibitors, angioten

30 e Pinto bean peptides with alpha-amylase and angiotensin converting enzyme (ACE) inhibitory activitie

31 nd 24 h resulted in the generation of potent angiotensin converting enzyme (ACE) inhibitory hydrolysa

32 resulted in the generation of highly potent angiotensin converting enzyme (ACE) inhibitory hydrolysa

33 Antioxidant and angiotensin converting enzyme (ACE) inhibitory peptides

34 ), several matrix metalloproteinases (MMPs), angiotensin converting enzyme (ACE), histone deacetylase

35 ive of this investigation was to compare the angiotensin converting enzyme (ACE)-inhibitory activity

36 ferric reducing antioxidant power (FRAP) and angiotensin-converting enzyme (ACE) assays.

37 Angiotensin-converting enzyme (ACE) can degrade Abeta(1-

38 Somatic angiotensin-converting enzyme (ACE) contains two active

39 The angiotensin-converting enzyme (ACE) deletion allele, ACE

40 The kidney is an important source of angiotensin-converting enzyme (ACE) in many species, inc

41 We predicted that the combination of an angiotensin-converting enzyme (ACE) inhibitor and a hist

42 Echocardiographic screening followed by angiotensin-converting enzyme (ACE) inhibitor and beta-b

43 To assess the effect of early angiotensin-converting enzyme (ACE) inhibitor therapy in

44 n reported to decrease time-to-resolution of angiotensin-converting enzyme (ACE) inhibitor-associated

45 ks compared with whites when treated with an angiotensin-converting enzyme (ACE) inhibitor-based regi

46 ; congestive heart failure (CHF) with use of angiotensin-converting enzyme (ACE) inhibitor.

47 The relative proportion of allergies to angiotensin-converting enzyme (ACE) inhibitors and HMG C

48 beta-Blockers and angiotensin-converting enzyme (ACE) inhibitors are widel

49 uses and may benefit from treatments such as angiotensin-converting enzyme (ACE) inhibitors for left

50 Angiotensin-converting enzyme (ACE) inhibitors have been

51 ge renal disease) when used as an adjunct to angiotensin-converting enzyme (ACE) inhibitors or angiot

52 ortality despite optimum treatment including angiotensin-converting enzyme (ACE) inhibitors or angiot

53 ents taking oral hypoglycemics, statins, and angiotensin-converting enzyme (ACE) inhibitors or angiot

54 ars 1990-2014 inclusive, using terms such as angiotensin-converting enzyme (ACE) inhibitors, adrenali

55 Interventions of interest were angiotensin-converting enzyme (ACE) inhibitors, angioten

56 Angiotensin-converting enzyme (ACE) inhibitors/angiotens

57 SNPs) at renin (REN), angiotensinogen (AGT), angiotensin-converting enzyme (ACE), angiotensin II type

58 ipeptidase, a peptidase related to mammalian angiotensin-converting enzyme (ACE), are insecticidal to

59 Angiotensin-converting enzyme (ACE)-2 is the primary enz

60 High-angiotensin-converting enzyme (ACE)-levels are associate

61 sates, which are efficient inhibitors of the angiotensin-converting enzyme (ACE).

62 Genes encoding angiotensin-converting enzymes (Ace and Ace2) are essent

63 glucosidase and alpha-amylase, inhibition of angiotensin-converting enzymes (ACE), and direct vaso-re

64 an angiotensin-receptor blocker (ARB) and an angiotensin-converting-enzyme (ACE) inhibitor (odds rati

65 at limit the efficacy of monotherapy with an angiotensin-converting-enzyme (ACE) inhibitor or angiote

66 Angioedema induced by treatment with angiotensin-converting-enzyme (ACE) inhibitors accounts

67 Combination therapy with angiotensin-converting-enzyme (ACE) inhibitors and angio

68 vels of albumin excretion might benefit from angiotensin-converting-enzyme (ACE) inhibitors and stati

69 Among patients with chronic heart failure, angiotensin-converting-enzyme (ACE) inhibitors reduce mo

70 For hydrolysates the antioxidant and angiotensin-converting-enzyme (ACE) inhibitory activitie

71 ha-amylase and alpha-glucosidase inhibition, angiotensin-converting-enzyme (ACE)-inhibition, antioxid

72 GET, 25 127 patients known to be tolerant to angiotensin-converting-enzyme (ACE)-inhibitors were rand

73 tory diagnostic biomarkers (eg, lysozyme and angiotensin-converting enzyme [ACE]) are lacking in high

74 odel with cardiac-specific overexpression of angiotensin-converting enzyme (ACE8/8), we demonstrated

75 These MPs exhibited angiotensin-converting enzyme activity and upregulated A

76 In addition, membrane-bound angiotensin-converting enzyme activity decreased.

77 ride-exposed and mechanical ventilated rats, angiotensin-converting enzyme activity in bronchoalveola

78 Increased serum levels of angiotensin converting enzyme and lysozyme are considere

79 ate the significance of differences in serum angiotensin converting enzyme and lysozyme levels of pat

80 The serum levels of angiotensin converting enzyme and lysozyme were analyzed

81 d the enzymatic cleavage of angiotensin I by angiotensin converting enzyme and monitored the increasi

82 s of the pulmonary renin-angiotensin system, angiotensin-converting enzyme, and angiotensin-convertin

83 for interleukin-6 receptor, chemokine CC-4, angiotensin-converting enzyme, and angiotensinogen, alth

84 ed by isolation of angiotensin, isolation of angiotensin-converting enzyme, and synthesis of its inhi

85 ension (n=32), during fixed Na(+) intake and angiotensin converting enzyme/angiotensin receptors bloc

86 ified on QiShenYiQi Pills using thrombin and angiotensin converting enzyme as "quality biomarkers".

87 Inhibition of angiotensin-converting enzyme before sepsis worsened the

88 of rats before cell transplantation with the angiotensin converting enzyme blocker, lisinopril, or an

89 sin II by a chymase-dependent rather than an angiotensin converting enzyme-dependent mechanism.

90 in downstream signaling pathways that induce angiotensin-converting enzyme expression and endothelial

91 elevation and 20-HETE-mediated increases in angiotensin-converting enzyme expression, endothelial dy

92 Chest radiography and serum angiotensin-converting enzyme findings were normal.

93 cluding dipeptidyl peptidase-IV (DPP-IV) and angiotensin converting enzyme I (ACE) inhibition, glucos

94 The angiotensin-converting enzyme I (rather than D) allele w

95 ultiple orthologs of the SARS receptor human angiotensin converting enzyme II (ACE2), replicate effic

96 lls, and the presence of angiotensinogen and angiotensin-converting enzyme in many tissues, renin rel

97 e activity and upregulated AT1 receptors and angiotensin-converting enzyme in P1 ECs.

98 these results indicate increased shedding of angiotensin-converting enzyme in the alveolar compartmen

99 l growth factor receptor phosphorylation and angiotensin-converting enzyme induction.

100 Finally, angiotensin-converting enzyme inhibition (captopril) nor

101 c effect of angiotensin receptor blockade or angiotensin-converting enzyme inhibition in DNP.

102 inhibition of local AngII production through angiotensin-converting enzyme inhibition prevented gluco

103 insulin therapy (RR 0.63; 95% CI 0.43-0.92), angiotensin-converting enzyme inhibition vs placebo (RR

104 ological functions, including antimicrobial, angiotensin-converting enzyme inhibition, antioxidant, o

105 nts with heart failure more effectively than angiotensin-converting enzyme inhibition.

106 duced residual albuminuria during fixed dose angiotensin-converting enzyme inhibition.

107 The angiotensin converting enzyme inhibitor lisinopril and m

108 e, primary renal disease classification, and angiotensin converting enzyme inhibitor or angiotensin r

109 tes mellitus and overt nephropathy receiving angiotensin converting enzyme inhibitor or angiotensin r

110 n, renal function, medication (beta-blocker, angiotensin converting enzyme inhibitor, and angiotensin

111 ioedema, hereditary angioedema type III, and angiotensin converting enzyme inhibitor-induced angioede

112 and without pretreatment with enalapril, an angiotensin converting enzyme inhibitor.

113 We then imaged the effects of angiotensin-converting enzyme inhibitor (5 mg/kg enalapr

114 There is no consensus whether angiotensin-converting enzyme inhibitor (ACEI) and angio

115 and an angiotensin receptor blocker (ARB) or angiotensin-converting enzyme inhibitor (ACEI) has demon

116 remental cost-effectiveness ratios (ICER) of angiotensin-converting enzyme inhibitor (ACEI), beta-blo

117 ective was to assess the association between angiotensin-converting enzyme inhibitor (ACEI)/angiotens

118 kground drug therapy, that is, high doses of angiotensin-converting enzyme inhibitor (ACEi, or angiot

119 harmacologic therapy that includes either an angiotensin-converting enzyme inhibitor (moderate-qualit

120 Angiotensin-converting enzyme inhibitor also significant

121 ptor blockers losartan and valsartan and the angiotensin-converting enzyme inhibitor captopril on wou

122 ium oxide nanoparticles for the detection of angiotensin-converting enzyme inhibitor drug, captopril,

123 sin inhibitor LCZ696 (400 mg daily) with the angiotensin-converting enzyme inhibitor enalapril (20 mg

124 ejection fraction (HFrEF), compared with the angiotensin-converting enzyme inhibitor enalapril, and i

125 ant prevented blood pressure lowering in the angiotensin-converting enzyme inhibitor group (p < 0.001

126 lood lactate was significantly higher in the angiotensin-converting enzyme inhibitor group than in th

127 ume withdrawn was significantly lower in the angiotensin-converting enzyme inhibitor group than in th

128 n, clopidogrel, beta-blocker, statin, and an angiotensin-converting enzyme inhibitor in patients with

129 nist-neprilysin inhibitor was superior to an angiotensin-converting enzyme inhibitor in reducing mort

130 Moreover, an angiotensin-converting enzyme inhibitor normalized CXCR4

131 without diabetes who are currently taking an angiotensin-converting enzyme inhibitor or an angiotensi

132 -angiotensin-aldosterone pathway, such as an angiotensin-converting enzyme inhibitor or an angiotensi

133 ack patients and 18.2% of patients not on an angiotensin-converting enzyme inhibitor or angiotensin I

134 oup had worse baseline renal function, lower angiotensin-converting enzyme inhibitor or angiotensin r

135 d as prescription of beta-blocker and either angiotensin-converting enzyme inhibitor or angiotensin r

136 l or add-on antihypertensive therapy with an angiotensin-converting enzyme inhibitor or angiotensin r

137 ssociation (NYHA) classification, and use of angiotensin-converting enzyme inhibitor or angiotensin r

138 Most patients (84%) used an angiotensin-converting enzyme inhibitor or angiotensin r

139 (<140 mm Hg systolic, <90 mm Hg diastolic), angiotensin-converting enzyme inhibitor or angiotensin r

140 every 1, 2, 5, or 10 years, with subsequent angiotensin-converting enzyme inhibitor or beta-blocker

141 estin 2, but not in MFS mice treated with an angiotensin-converting enzyme inhibitor or lacking angio

142 It is an angiotensin-converting enzyme inhibitor that operates vi

143 treatment of avascular necrosis, and use of angiotensin-converting enzyme inhibitor therapy for micr

144 ia could identify patients with COPD in whom angiotensin-converting enzyme inhibitor therapy improves

145 effectiveness of sacubitril-valsartan versus angiotensin-converting enzyme inhibitor therapy in patie

146 hod to follow the immunomodulatory impact of angiotensin-converting enzyme inhibitor therapy on myelo

147 who derive significant clinical benefit from angiotensin-converting enzyme inhibitor therapy regardle

148 lled in the PEACE (Prevention of Events With Angiotensin-Converting Enzyme Inhibitor Therapy) trial.

149 nts who derive greater clinical benefit from angiotensin-converting enzyme inhibitor therapy.

150 tensin Receptor-Neprilysin Inhibitor With an Angiotensin-Converting Enzyme Inhibitor to Determine Imp

151 nuates the deleterious hemodynamic effect of angiotensin-converting enzyme inhibitor treatment in mic

152 resent findings support the possibility that angiotensin-converting enzyme inhibitor treatment might

153 with HF; however, retrospective analysis of angiotensin-converting enzyme inhibitor trials and prosp

154 sure, and no angiotensin II receptor blocker/angiotensin-converting enzyme inhibitor use were associa

155 RAAS inhibition by enalapril (angiotensin-converting enzyme inhibitor) or losartan (an

156 in-receptor-neprilysin inhibitor) with ACEI (angiotensin-converting enzyme inhibitor) to Determine Im

157 , 378 (9.2%) were taking azathioprine and an angiotensin-converting enzyme inhibitor, 171 (12.9%) wer

158 to support initiating drug treatment with an angiotensin-converting enzyme inhibitor, angiotensin rec

159 wer of DPM, three effect categories, namely, angiotensin-converting enzyme inhibitor, cyclooxygenase

160 Her medications include a beta-blocker, angiotensin-converting enzyme inhibitor, oral antidiabet

161 ption of antiplatelet agents, beta-blockers, angiotensin-converting enzyme inhibitor, statins at disc

162 The benefit of sacubitril/valsartan, over an angiotensin-converting enzyme inhibitor, was consistent

163 edema, acquired C1 inhibitor deficiency, and angiotensin-converting enzyme inhibitor-associated angio

164 eceptor blockade during hemorrhagic shock in angiotensin-converting enzyme inhibitor-treated mice.

165 This benefit could be of interest in angiotensin-converting enzyme inhibitor-treated patients

166 nary intervention, in-hospital and discharge angiotensin-converting enzyme inhibitor/angiotensin II r

167 to receive treatment with a beta-blocker, an angiotensin-converting enzyme inhibitor/angiotensin II r

168 nts' baseline characteristics (shock, use of angiotensin-converting enzyme inhibitor/angiotensin II r

169 antiplatelet drug, statin, beta-blocker, and angiotensin-converting enzyme inhibitor/angiotensin rece

170 B-type natriuretic peptide, pkVO2, NYHA, and angiotensin-converting enzyme inhibitor/angiotensin rece

171 and statins but were less likely to receive angiotensin-converting enzyme inhibitor/angiotensin rece

172 thin 24 hours, (2) aspirin at discharge, (3) angiotensin-converting enzyme inhibitor/angiotensin rece

173 445-patient subset received at least 1 GDMT (angiotensin-converting enzyme inhibitor/angiotensin rece

174 s a combination of statin, beta-blocker, and angiotensin-converting enzyme inhibitor/angiotensin rece

175 get (95/60 to 110/75 mm Hg) and to either an angiotensin-converting-enzyme inhibitor (lisinopril) plu

176 in Receptor-Neprilysin Inhibitor] with ACEI [Angiotensin-Converting-Enzyme Inhibitor] to Determine Im

177 in Receptor-Neprilysin Inhibitor] With ACEI [Angiotensin-Converting-Enzyme Inhibitor] to Determine Im

178 in Receptor-Neprilysin Inhibitor] with ACEI [Angiotensin-Converting-Enzyme Inhibitor] to Determine Im

179 The occurrence of the casein-derived angiotensin converting enzyme-inhibitor (ACE-I) peptides

180 bitril/valsartan was more effective than the angiotensin-converting enzyme inhibitorenalapril in pati

181 s indicated that angiotensin II (Ang II) and angiotensin converting enzyme inhibitors regulated blood

182 d were more often on diuretics, digoxin, and angiotensin converting enzyme inhibitors.

183 lled trial planned to evaluate the impact of angiotensin-converting enzyme inhibitors (ACE-i) on the

184 al of the study was to assess the effects of angiotensin-converting enzyme inhibitors (ACE-Is) and an

185 The association between angiotensin-converting enzyme inhibitors (ACEI) and angi

186 Angiotensin-converting enzyme inhibitors (ACEi) for reni

187 round clinician-directed therapy with either angiotensin-converting enzyme inhibitors (ACEI) or angio

188 Angiotensin-converting enzyme inhibitors (ACEI) or angio

189 Although statins, angiotensin-converting enzyme inhibitors (ACEI) or angio

190 We focused on angiotensin-converting enzyme inhibitors (ACEI), angiote

191 re with reduced ejection fraction, including angiotensin-converting enzyme inhibitors (ACEI), angiote

192 eatment doses of beta-blockers, statins, and angiotensin-converting enzyme inhibitors (ACEI)/angioten

193 Reduced potassium excretion caused by angiotensin-converting enzyme inhibitors (ACEis) and ang

194 Angiotensin-converting enzyme inhibitors (ACEIs) may ret

195 Angiotensin-converting enzyme inhibitors (ACEIs) or angi

196 Angiotensin-converting enzyme inhibitors (ACEIs) or angi

197 hough several studies have shown that use of angiotensin-converting enzyme inhibitors (ACEIs) potenti

198 rm use of calcium channel blockers (CCBs) or angiotensin-converting enzyme inhibitors (ACEis), respec

199 but an increased risk was found for users of angiotensin-converting enzyme inhibitors (adjusted OR 1

200 nsin II type 1 receptor antagonists (n=6) or angiotensin-converting enzyme inhibitors (n=6) exhibited

201 ant (HOE-140) immediately before anesthesia (angiotensin-converting enzyme inhibitors + icatibant), a

202 dication use (antiplatelet therapy, statins, angiotensin-converting enzyme inhibitors [ACEIs] or angi

203 ondition for which the medication was taken (angiotensin-converting enzyme inhibitors [ACEIs], angiot

204 orrhagic shock, 4) shocked mice treated with angiotensin-converting enzyme inhibitors and a single bo

205 ssessed for each of 6 drug classes: statins, angiotensin-converting enzyme inhibitors and angiotensin

206 Uptitration of angiotensin-converting enzyme inhibitors and beta blocke

207 Angiotensin-converting enzyme inhibitors and beta-blocke

208 Angiotensin-converting enzyme inhibitors and beta-blocke

209 We hypothesized that angiotensin-converting enzyme inhibitors and beta-blocke

210 Current standard therapy with angiotensin-converting enzyme inhibitors and/or angioten

211 Angiotensin-converting enzyme inhibitors are associated

212 Because the pharmacologic effects of angiotensin-converting enzyme inhibitors are partly medi

213 Angiotensin-converting enzyme inhibitors can delay the p

214 should include calcium channel blockers and angiotensin-converting enzyme inhibitors for cardiovascu

215 lasses: aspirin, statins, beta-blockers, and angiotensin-converting enzyme inhibitors given to patien

216 Many vasodilators including angiotensin-converting enzyme inhibitors have been evalu

217 Intracoronary angiotensin-converting enzyme inhibitors have been shown

218 s support the need to reevaluate the role of angiotensin-converting enzyme inhibitors in humans with

219 atory profile, and were less likely to be on angiotensin-converting enzyme inhibitors or aldosterone

220 bing, indications, and contraindications for angiotensin-converting enzyme inhibitors or angiotensin

221 vention medications (statins, beta-blockers, angiotensin-converting enzyme inhibitors or angiotensin

222 giotensin-aldosterone system with the use of angiotensin-converting enzyme inhibitors or angiotensin

223 ary discharge diagnosis of HF, initiation of angiotensin-converting enzyme inhibitors or angiotensin

224 ose eligible at discharge were not receiving angiotensin-converting enzyme inhibitors or angiotensin

225 and 88% were receiving beta-blockers and 81% angiotensin-converting enzyme inhibitors or angiotensin

226 0.017) but not among those only treated with angiotensin-converting enzyme inhibitors or angiotensin

227 beta-blockers, angiotensin-converting enzyme inhibitors or angiotensin

228 e of antihypertensive medications other than angiotensin-converting enzyme inhibitors or angiotensin

229 Time-dependent effects of angiotensin-converting enzyme inhibitors or angiotensin

230 re, where use of beta-blockers, statins, and angiotensin-converting enzyme inhibitors or angiotensin

231 95% CI, 0.75-0.99; P = 0.030) and trends for angiotensin-converting enzyme inhibitors or angiotensin

232 were receiving insulin, and 84% were taking angiotensin-converting enzyme inhibitors or angiotensin

233 opathy and proteinuria >1 g/d, maintained on angiotensin-converting enzyme inhibitors or angiotensin

234 ck patients and patients with intolerance to angiotensin-converting enzyme inhibitors or angiotensin

235 elet P2Y12 receptor inhibitors, statins, and angiotensin-converting enzyme inhibitors or angiotensin

236 All patients were treated with angiotensin-converting enzyme inhibitors or angiotensin-

237 giotensin system (RAS) blockade therapy with angiotensin-converting enzyme inhibitors or angiotensin-

238 Patients who were prescribed angiotensin-converting enzyme inhibitors or angiotensin-

239 sting), prescribing appropriate medications (angiotensin-converting enzyme inhibitors or angiotensin-

240 sting), prescribing appropriate medications (angiotensin-converting enzyme inhibitors or angiotensin-

241 th literacy and less likely to be prescribed angiotensin-converting enzyme inhibitors or beta-blocker

242 As predicted, BALB/c mice pretreated with angiotensin-converting enzyme inhibitors potentiated IFN

243 Further, angiotensin-converting enzyme inhibitors potentiated TCT

244 m, as evidenced by trials that have compared angiotensin-converting enzyme inhibitors with drugs that

245 eurohormonal activity (like beta-blockers or angiotensin-converting enzyme inhibitors) are considered

246 ocked mice treated with ramipril for 7 days (angiotensin-converting enzyme inhibitors) before hemorrh

247 , statins, angiotensin II receptor blockers, angiotensin-converting enzyme inhibitors) can modify the

248 [CI]: 49%-64%) of patients were treated with angiotensin-converting enzyme inhibitors, 34% (95% CI: 2

249 itration of beta-adrenergic blocking agents, angiotensin-converting enzyme inhibitors, and angiotensi

250 r disease medicines (aspirin, beta blockers, angiotensin-converting enzyme inhibitors, and statins) i

251 scharge included the following: medications (angiotensin-converting enzyme inhibitors, angiotensin II

252 Angiotensin-converting enzyme inhibitors, angiotensin re

253 atio [UPCR] 500-5000 mg/g) and taking stable angiotensin-converting enzyme inhibitors, angiotensin re

254 g or higher on permitted background drugs of angiotensin-converting enzyme inhibitors, angiotensin-re

255 No class of medications (i.e., angiotensin-converting enzyme inhibitors, angiotensin-re

256 The medication classes examined were angiotensin-converting enzyme inhibitors, angiotensin-re

257 d and then subsequently filled prescriptions angiotensin-converting enzyme inhibitors, beta-blockers,

258 ar complications have also been treated with angiotensin-converting enzyme inhibitors, beta-blockers,

259 that promoted antiplatelet agents, statins, angiotensin-converting enzyme inhibitors, blood pressure

260 patients more often received beta-blockers, angiotensin-converting enzyme inhibitors, nitrates, and

261 ary coverage for all statins, beta-blockers, angiotensin-converting enzyme inhibitors, or angiotensin

262 g proportion of days covered for statins and angiotensin-converting enzyme inhibitors, patients were

263 hereas 91% and 54% were on beta-blockers and angiotensin-converting enzyme inhibitors, respectively.

264 ives (eOC), hormonal replacement therapy, or angiotensin-converting enzyme inhibitors.

265 roteinuric angiotensin receptor blockers and angiotensin-converting enzyme inhibitors.

266 and 0.86 (0.74-1.01) in patients on statins, angiotensin-converting enzyme inhibitors/angiotensin rec

267 e of and patient adherence to beta-blockers, angiotensin-converting enzyme inhibitors/angiotensin rec

268 vention with a combination of beta-blockers, angiotensin-converting enzyme inhibitors/angiotensin rec

269 f 85 017 individuals, 55%, 76%, and 61% used angiotensin-converting enzyme inhibitors/angiotensin rec

270 ethnicity, but women were less likely to use angiotensin-converting enzyme inhibitors/angiotensin rec

271 Rates of patients receiving angiotensin-converting enzyme inhibitors/angiotensin rec

272 escription rates ranged from 44% to 100% for angiotensin-converting enzyme inhibitors/angiotensin rec

273 Practice rates of treatment with angiotensin-converting enzyme inhibitors/angiotensin rec

274 .11 (95% confidence interval, 1.08-1.18) for angiotensin-converting enzyme inhibitors/angiotensin rec

275 Successive eras had greater usage of angiotensin-converting enzyme inhibitors/angiotensin rec

276 ficial effects of treatment with statins and angiotensin-converting enzyme inhibitors/angiotensin rec

277 , and 66.4% of the patients were on statins, angiotensin-converting enzyme inhibitors/angiotensin rec

278 es were treatment at discharge with statins, angiotensin-converting enzyme inhibitors/angiotensin rec

279 versus 57% in rural; P=0.1) and reversed for angiotensin-converting enzyme inhibitors/angiotensin rec

280 , documentation of ejection fraction, use of angiotensin-converting enzyme inhibitors/angiotensin rec

281 0.8 [95% confidence interval, 0.64-0.98] for angiotensin-converting enzyme inhibitors; and relative r

282 blockers, angiotensin receptor blockers, and angiotensin-converting enzyme inhibitors; prophylactic s

283 s a metabolite significantly associated with angiotensin-converting-enzyme inhibitors in our metabolo

284 ential introduction of medications including angiotensin-converting-enzyme inhibitors, angiotensin-re

285 yric acid (GABA) content (6.8-10.6 mg/g) and angiotensin converting enzyme inhibitory (ACEI) activity

286 The angiotensin converting enzyme-inhibitory activity was si

287 Laboratory results showed high angiotensin converting enzyme level being significantly

288 There was a significant increase in serum angiotensin converting enzyme level in patients with pre

289 al serum chemistry, including a normal serum angiotensin-converting enzyme level.

290 Elevated serum angiotensin converting enzyme levels are significant for

291 o were nonadherent to beta-blockers, whereas angiotensin-converting enzyme or angiotensin II receptor

292 bocytosis and sickle cell anaemia, and serum angiotensin-converting enzyme (SACE) measurement to excl

293 Somatic angiotensin-converting enzyme (sACE), a key regulator of

294 Together with the presence of angiotensin-converting enzyme-sheddase ADAM9 (a disinteg

295 Inhibition of angiotensin-converting enzyme slows progression to kidne

296 within the PEACE (Prevention of Events With Angiotensin-Converting Enzyme) trial and followed up for

297 at it is also associated with a reduction of angiotensin-converting enzyme type 2 (ACE2) and an incre

298 Although overexpression of angiotensin-converting enzyme type 2 (ACE2) has been sho

299 The activity of angiotensin-converting enzyme, which catalyses productio

300 the balance toward the lung injury-promoting angiotensin-converting enzyme, which may form an explana